<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532740</url>
  </required_header>
  <id_info>
    <org_study_id>NU 1365-002</org_study_id>
    <secondary_id>P30CA060553</secondary_id>
    <secondary_id>NU-1365-002</secondary_id>
    <nct_id>NCT00532740</nct_id>
  </id_info>
  <brief_title>Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Humanitarian Device Exemption Compassionate Use Protocol of TheraSphere for Treatment of Unresectable Metastatic Cancer to the Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near&#xD;
      a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be&#xD;
      effective treatment for liver cancer that cannot be removed by surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well radiolabeled glass beads work in treating&#xD;
      patients with metastatic liver cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Provide supervised access to treatment with yttrium Y 90 glass microspheres&#xD;
           (TheraSphere®) to eligible patients who are not candidates for surgical resection of&#xD;
           metastatic intrahepatic carcinoma.&#xD;
&#xD;
        -  Evaluate patient experience and toxicities associated with yttrium Y 90 glass&#xD;
           microspheres treatment.&#xD;
&#xD;
      OUTLINE: This is a humanitarian device exemption use study.&#xD;
&#xD;
      Patients receive yttrium Y 90 glass microspheres (TheraSphere®) into the liver tumor through&#xD;
      a percutaneously placed catheter into the hepatic artery. Patients may receive additional&#xD;
      therapy 4-12 weeks after initial treatment at the discretion of the study physician.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 2 weeks, 30 days, and then once a&#xD;
      year for approximately 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>All Patients</arm_group_label>
    <description>Patients with metastatic cancer of the liver who are not surgical resection candidates and who will be treated with TheraSphere per institutional standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y 90 glass microspheres</intervention_name>
    <description>Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.</description>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic cancer of the liver who are not surgical resection candidates.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of metastatic intrahepatic carcinoma&#xD;
&#xD;
               -  Histopathology confirmation may be waived in patients with a radiographically&#xD;
                  identifiable liver mass AND known laboratory or clinical risk factors for cancer&#xD;
                  or elevated tumor markers such as AFP&#xD;
&#xD;
          -  Unresectable disease&#xD;
&#xD;
          -  No portal hypertension with portal venous shunt away from the liver&#xD;
&#xD;
          -  FDA approval to receive compassionate use of yttrium Y 90 glass microspheres&#xD;
&#xD;
          -  No significant extrahepatic disease representing an imminent life-threatening outcome&#xD;
&#xD;
          -  No evidence of potential delivery of &gt; 16.5 mCi (30 Gy absorbed dose) of radiation to&#xD;
             the lungs on either of the following:&#xD;
&#xD;
               -  First administration of yttrium Y 90 glass microspheres (TheraSphere ®)&#xD;
&#xD;
               -  Cumulative delivery of radiotherapy to the lungs over multiple treatments&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/µL&#xD;
&#xD;
          -  Platelet count ≥ 25,000/μL&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL (unless using non-iodinated contrast or on dialysis)&#xD;
&#xD;
          -  Serum bilirubin ≤ 3.0 mg/dL (in some cases where there is an elevated bilirubin, and&#xD;
             the tumor may be isolated from a vascular standpoint, treatment may proceed)&#xD;
&#xD;
          -  No contraindication to angiography or selective visceral catheterization, including&#xD;
             any of the following:&#xD;
&#xD;
               -  History of severe allergy or intolerance to any contrast media, narcotics,&#xD;
                  sedatives, or atropine, that cannot be controlled using basic angiographic&#xD;
                  techniques&#xD;
&#xD;
               -  Bleeding diathesis, not correctable by usual forms of therapy&#xD;
&#xD;
               -  Severe peripheral vascular disease that would preclude catheterization&#xD;
&#xD;
          -  No severe liver dysfunction or pulmonary insufficiency&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No significant underlying medical or psychiatric illness&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No evidence of any detectable technetium-99 macroaggregated albumin (Tc-99 MAA) flow&#xD;
             to the stomach or duodenum after application of established angiographic techniques to&#xD;
             stop such flow&#xD;
&#xD;
          -  No comorbid disease or condition that would preclude safe delivery of yttrium Y 90&#xD;
             glass microspheres and place patient at undue risk&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior surgery&#xD;
&#xD;
          -  At least 2 weeks since prior radiosensitizing chemotherapy&#xD;
&#xD;
          -  More than 6 weeks since prior carmustine (BCNU) or mitomycin C&#xD;
&#xD;
          -  No other concurrent cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riad Salem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, Benson AB 3rd, Kennedy AS, Omary RA, Salem R. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008 Jun;247(6):1029-35. doi: 10.1097/SLA.0b013e3181728a45.</citation>
    <PMID>18520231</PMID>
  </results_reference>
  <results_reference>
    <citation>Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology. 2008 May;247(2):507-15. doi: 10.1148/radiol.2472062029. Epub 2008 Mar 18.</citation>
    <PMID>18349311</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver metastases</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

